Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Subjects enrolled in the study will be randomized to receive investigational product (MTX101 2mg or placebo), to be taken as soon as they have a migraine headache that reaches moderate to severe intensity. Subjects will take a single dose of either active or placebo to treat one migraine headache. Rescue medication should not be taken until at least 2 hours post study medication dose. The subject will have a telephone check up within 72 to 120 hours after treatment of the first migraine headache. The subject will treat a 2nd moderate to severe migraine at least 48 hours after the first treated migraine headache. The subject will return to the clinic for re-evaluation within a 4 week period from the start of the study.